A guide for people who aspire to practice as venture capitalists and also for those interested in gaining in-depth knowledge of the rigid system of venture capital. It explores the various aspects of venture capital investing. Almost 25% of venture capital companies are successful, while one third of them go bankrupt. Around 40% of these companies face difficulties coping with the growing economy. the companies in these different categories are respectively termed the good, the bad and the living dead.
This book is about selectively toxic agents. That is to say, it is about those substances that affect certain cells without harming others, even when they are close neighbours. Toxicity need not be fatal. It can be made easily reversible, as is the case with general anaesthetics. Selective toxicity covers an immense field: most of the drugs used for treating illness in man and his economic animals, as well as all of the fungicides, insecticides, and weed killers that are used in agriculture. Essentially, this book is a discussion of the physical and chemical means which contribute to selectivity, and this is the basis of molecular pharmacology. _Selective Toxicity began as a course of lectures that Professor F. G. Young encouraged me to give in University College London, in 1948 and again in 1949. The first edition appeared in 1951, as a very small book because little was then known about the factors that provide selectivity. Since those early days, the subject has undergone tremendous development. At first, industry was un receptive to the word 'toxicity', however qualified! Yet the market was being supplied with biologically powerful substances of which several had the potential to cause harm. This aspect was brought to light by two events of the early 1960s. The first of these was the discovery that a sedative, thalidomide, administered to expectant mothers, after what was then considered to be adequate testing, had caused permanent deformities in about 10000 children.
The story recounted in this book is the attempt of the historic peace churches (Friends, Mennonites, and the Church of the Brethren) to gain alternative service for conscientious objectors to war from 1917 to 1955 in the United States. The primary focus is on the forty-year effort to establish an historic peace church conscientious machinery of the American warfare state. This is the first book to attempt to fully reconstruct that effort.
Walk into any hospital room and you are likely to find infusion pumps bearing the IMED or IVAC names. Stories of these companies convey themes typical of venture finance technological innovation driving higher valuations leading to a spectacular sale. (use italics in yellow/gold)These five broadly different case studies of major healthcare device companies and a biotechnology start-up to public company provide the reader with a rich cross section of business issues and answers. This book should be of interest to anyone in the health care industry, as well as to the general business reader. The cases provide a venture capitalist's and manager's view of how to start and build a company.The author was lead VC in each of these five companies. There is a detailed description of the issues and problems which occur in developing young companies to create significant value. The way problems and successes were dealt with gives the reader a broad learning experience ranging from the damage of patent infringement to being first in a market with runaway initial acceptance and learning how to keep the lead.Each of these cases comes from Henry Venture Fund investments. The reader learns how the investment opportunity was analyzed, how the investment was priced, how it was managed and directed into its product development and principal markets, and whether success or failure occurred and why. Two of the companies were sold for $400 million each, one was sold for $80 million in 22 months from founding, one declined in value by 90%, or $100 million, and was acquired and taken private and the the biotech company went public.Also included are two new biotech company descriptions which have made significant scientific discoveries. Sinapis Pharma has commenced a human clinical trial for brain trauma and stroke indications. TauTaTis is a preclinical company in Alzheimer's and Parkinson's Disease with very promising scientific data in mouse studies
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.